 induct sustain patenc clot-select coronari thrombolysi hybrid-b plasminogen activ prolong biolog half-lif background util tissue-typ plasminogen activ t-pa coronari thrombolysi earli reocclus problem anticoagul patient success recan studi util hybrid-b molecular variant t-pa prolong half-lif circul coronari thrombolysi patenc presenc thrombogen stimulu method result intact anesthet dog mg hybrid-b minut mg t-pa activas minut minut left anterior coronari arteri occlus thrombogen copper coil time averag SD minut minut hybrid-b t-pa NS hybrid-b bolu mg minut high initi concentr blood time lysi minut dog hybrid-b infus bolu prolong time reocclus minut minut dog t-pa mainten subthrombolyt activ concentr activ blood persist hybrid-b blood concentr fibrinogen alpha control valu conclus thu hybrid-b novel variant t-pa uniqu pharmacokinet properti elicit clot-select coronari thrombolysi